‘Arimidex’ (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer-efficacy overview
Author:
Publisher
Elsevier BV
Subject
Cell Biology,Clinical Biochemistry,Endocrinology,Molecular Biology,Molecular Medicine,Biochemistry,Endocrinology, Diabetes and Metabolism
Reference9 articles.
1. A phase III trial comparing anastrozole (1 and 10 mg), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma;Buzdar;Cancer,1997
2. A randomized trial comparing two doses of the new selective aromatase inhibitor (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer;Jonat W;Eur. J. Cancer,1996
3. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature Phase III trials;Buzdar;Cancer,1998
4. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial;Nabholtz;J. Clin. Oncol.,2000
5. The ATAC Trialists’ Group, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial, Lancet 359 (2002) 2131–2139.
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Osteoporotic Fractures of the Spine, Hip, and Other Locations after Adjuvant Endocrine Therapy with Aromatase Inhibitors in Breast Cancer Patients: a Meta-analysis;Journal of Korean Medical Science;2020
2. Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome‐Wide Association Study: Functional Epistatic Interaction Between SLC 38A7 and ALPPL 2;Clinical Pharmacology & Therapeutics;2019-03-18
3. Breast Cancer;Radiation Oncology;2019
4. Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis;Therapeutic Advances in Musculoskeletal Disease;2018-03-22
5. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain;Clinical and Translational Oncology;2017-11-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3